| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| References | |
|---|---|
| Additional Infomation |
Vicadrostat is a small molecule drug. The International Nonproprietary Name (INN) stem "-drostat" in its name indicates that vecarstat is an inhibitor of aldosterone and cortisol synthesis. Vicadrostat is currently undergoing clinical trials (NCT07064473) (a study testing the efficacy of vecarstat (BI 690517) in combination with empagliflozin in patients with type 2 diabetes, hypertension, and cardiovascular disease). The monoisotope molecular weight of vecarstat is 317.06 Da.
|
| Molecular Formula |
C15H12CLN3O3
|
|---|---|
| Molecular Weight |
317.73
|
| Exact Mass |
317.057
|
| CAS # |
1868065-21-7
|
| PubChem CID |
118676295
|
| Appearance |
White to off-white solid
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
22
|
| Complexity |
508
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C[C@@]1(CC2=C(C(=O)O1)N(C=N2)C3=CC(=C(C=C3)C#N)Cl)CO
|
| InChi Key |
MCVIVPZYYMNCAW-OAHLLOKOSA-N
|
| InChi Code |
InChI=1S/C15H12ClN3O3/c1-15(7-20)5-12-13(14(21)22-15)19(8-18-12)10-3-2-9(6-17)11(16)4-10/h2-4,8,20H,5,7H2,1H3/t15-/m1/s1
|
| Chemical Name |
2-chloro-4-[(6R)-6-(hydroxymethyl)-6-methyl-4-oxo-7H-pyrano[3,4-d]imidazol-3-yl]benzonitrile
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~314.7 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.87 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (7.87 mM) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Suspended solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1473 mL | 15.7366 mL | 31.4733 mL | |
| 5 mM | 0.6295 mL | 3.1473 mL | 6.2947 mL | |
| 10 mM | 0.3147 mL | 1.5737 mL | 3.1473 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT06424288
Conditions:Heart FailureLink: https://clinicaltrials.gov/ct2/show/NCT07064473
Conditions:Diabetes Mellitus, Type 2|Hypertension|Cardiovascular DiseasesLink: https://clinicaltrials.gov/ct2/show/NCT06935370
Conditions:Heart Failure
Title:A Study in Healthy People to Test How Vicadrostat Affects the Heart
Status:Recruiting
updateDate:2026-05-12
Ctid:NCT07513207
Link: https://clinicaltrials.gov/ct2/show/NCT07513207
Conditions:HealthyLink: https://clinicaltrials.gov/ct2/show/NCT06926660
Conditions:Chronic Kidney DiseaseLink: https://clinicaltrials.gov/ct2/show/NCT07035457
Conditions:HealthyProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
